Clene Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 79

Employees

  • Stock Symbol
  • CLNN

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $3.74
  • (As of Monday Closing)

Clene General Information

Description

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Contact Information

Website
www.clene.com
Formerly Known As
Chelsea Worldwide
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 6550 South Millrock Drive
  • Suite G50
  • Salt Lake City, UT 84121
  • United States
+1 (801)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 6550 South Millrock Drive
  • Suite G50
  • Salt Lake City, UT 84121
  • United States
+1 (801)

Clene Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Clene Stock Performance

As of 16-Nov-2026, Clene’s stock price is $3.74. Its current market cap is $53.9M with 14.4M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.74 $3.97 $3.02 - $10.84 $53.9M 14.4M 107K -$2.30

Clene Financials Summary

As of 30-Sep-2026, Clene has a trailing 12-month revenue of $238K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 70,666 74,047 50,608 27,890
Revenue 238 200 342 654
EBITDA (22,704) (22,219) (34,556) (44,630)
Net Income (26,826) (26,173) (39,400) (49,504)
Total Assets 22,157 18,131 27,337 52,341
Total Debt 22,604 21,673 20,843 32,161
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Clene Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Clene‘s full profile, request access.

Request a free trial

Clene Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Clene‘s full profile, request access.

Request a free trial

Clene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of nov
Drug Discovery
Salt Lake City, UT
79 As of 2025

Basking Ridge, NJ
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Clene Competitors (25)

One of Clene’s 25 competitors is Lisata Therapeutics, a Corporation company based in Basking Ridge, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lisata Therapeutics Corporation Basking Ridge, NJ
Denali Therapeutics Formerly VC-backed South San Francisco, CA
Organogenesis Holdings Pending Transaction (M&A) Canton, MA
Octane Medical Group Corporate Backed or Acquired Kingston, Canada
Capricor Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 25 competitors. Get the full list »

Clene Patents

Clene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2014262673-A1 Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination Active 08-May-2013
AU-2014262673-B2 Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination Active 08-May-2013
CA-2913205-A1 Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination Active 08-May-2013
CA-2913205-C Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination Active 08-May-2013
EP-2994146-A2 Methods and treatment for certain demyelination and dysmyelination-based disorders and/or promoting remyelination Active 08-May-2013 A61K33/24
To view Clene’s complete patent history, request access »

Clene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Clene Acquisitions (1)

Clene’s most recent deal was a Merger/Acquisition with Tottenham Acquisition. The deal was made on 30-Dec-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tottenham Acquisition 30-Dec-2020 Merger/Acquisition Special Purpose Acquisition Company (SPAC)
To view Clene’s complete acquisitions history, request access »

Clene ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

38.48 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Clene’s complete esg history, request access »

Clene FAQs

  • When was Clene founded?

    Clene was founded in 2012.

  • Where is Clene headquartered?

    Clene is headquartered in Salt Lake City, UT.

  • What is the size of Clene?

    Clene has 79 total employees.

  • What industry is Clene in?

    Clene’s primary industry is Drug Discovery.

  • Is Clene a private or public company?

    Clene is a Public company.

  • What is Clene’s stock symbol?

    The ticker symbol for Clene is CLNN.

  • What is the current stock price of Clene?

    As of 16-Nov-2026 the stock price of Clene is $3.74.

  • What is the current market cap of Clene?

    The current market capitalization of Clene is $53.9M.

  • What is Clene’s current revenue?

    The trailing twelve month revenue for Clene is $238K.

  • Who are Clene’s competitors?

    Lisata Therapeutics, Denali Therapeutics, Organogenesis Holdings, Octane Medical Group, and Capricor Therapeutics are some of the 25 competitors of Clene.

  • What is Clene’s annual earnings per share (EPS)?

    Clene’s EPS for 12 months was -$2.30.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process